Angiostatic effects of suramin analogs in vitro

Anti-Cancer Drugs

Volumn 11, Issue 2, 2000, Pages 69-77

  Firsching Hauck, Angela ^a   Nickel, Peter ^b   Yahya, Claudia ^a   Wandt, Carla ^b   Kulik, Renate ^b   Simon, Nicola ^b   Zink, Martina ^a   Nehls, Volker ^a   Allolio, Bruno ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Microcarrier angiogenesis assay; Structure activity relationship; Suramin; Suramin analogs

Indexed keywords

ANTINEOPLASTIC AGENT; NF 062; NF 108; NF 109; NF 241; NF 289; NF 326; NF 499; NF 500; NF 520; NF 527; NF 528; NF 529; SURAMIN; SURAMIN ANALOG; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; AORTA; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HT29 CELLS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; SURAMIN; SWINE; TUMOR CELLS, CULTURED;

EID: 0034126238     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200002000-00002     Document Type: Article

References (39)

1. Hawking F. Suramin with special reference to onchocerciasis. Adv Pharmacol Chemother 1978; 15: 289-322.
2. La Rocca RV, Stein CA, Danesi R, Uhrich M, Myers CE. A pilot study of suramin in the treatment of metastatic renal carcinoma. Cancer 1991; 67: 1509-13.
3. La Rocca RV, Stein CA, Danesi R, Jamis-Dow CA, Weiss GH, Myers CE. Suramin in adrenal cancer: Modulation of steroid hormone production, cytotoxicity in vitro and clinical antitumour effect. J Clin Endocrinol Metab 1990; 71: 497-504.
4. Arlt W, Reincke M, Siekmann L, Winkelmann W, Allolio B. Suramin in adrenocortical cancer: Limited efficacy and serious toxicity. Clin Endocrinol 1994; 41: 299-307.
5. Allolio B, Reincke M, Jaursch-Hanke C, Arlt W, Winkelmann W. Treatment of metastatic adrenocortical carcinoma with suramin. Dtsch Med Wochenschr 1989; 114: 381-4.
6. Reed E, Cooper MR, LaRocca RV, Bostick-Bruton F, Myers CE. Suramin in advanced platinum-resistant ovarian cancer. Eur J Cancer 1992; 28A: 864-6.
7. La Rocca RV, Myers CE, Stein CA, Cooper MR, Uhrich M. Effect of suramin in patients with refractory nodular lymphomas requiring systemic therapy. Proc Am Soc Clin Oncol 1990b; 9: 268.
8. Dawson NA, Figg WD, Cooper MR, et al. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997; 15: 1470-7.
9. Myers C, Cooper M, Stein CA, et al. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992; 10: 881-9.
10. Eisenberger MA, Sinibaldi VJ, Reyno LM, et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 1995; 13: 2174-86.
11. Miglietta L, Canobbio L, Granetto C, Vanozzi MO, Esposito M, Boccardo F. Suramin/epidoxurubicin association in hormone-refractory prostate cancer: Preliminary results of a pilot phase II study. J Cancer Res Clin Oncol 1997; 123: 407-10.
12. Spigelman Z, Dowers A, Kennedy S, et al. Antiproliferative effects of suramin on lymphoid cells. Cancer Res 1987; 47: 4694-8.
13. Firsching A, Nickel P, Mora P, Allolio B. Antiproliferative and angiostatic activity of suramin analogues. Cancer Res 1995; 55: 4957-61.
14. Coffey R, Leof E, Shipley GD, Moses HL. Suramin inhibition of growth factor receptor binding and mitogenicity in ARK-2B cells. J Cell Physiol 1987; 132: 143-8.
15. Pollack M, Richard M. Suramin blockade of insulin-like growth factor i-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 1990, 82: 1349-52.
16. Middaugh CR, Mach H, Burke CJ, et al. Nature of the interaction of growth factors with suramin. Biochemistry 1992; 31: 9016-24.
17. Kopp R, Pfeiffer A. Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. Cancer Res 1990; 50: 6490-6.
18. Olivier S, Formento P, Fischel JL, Etienne MC, Milano G. Epidermal growth factor receptor expression and suramin cytotoxicity in vitro. Eur J Cancer 1990; 26: 867-71.
19. Hosang M. Suramin binds to platelet growth factor and inhibits its biological activity. J Cell Biochem 1985; 29: 265-73.
20. Olander JV, Connolly DT, DeLarco JE. Specific binding of vascular permeability factor to endothelial cells. Biochem Biophys Res Commun 1991; 175: 68-76.
21. Hensey CE, Bosboinik D, Azzi A. Suramin, an anticancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett 1989; 258: 156-8.
22. Funayama Y, Nishio K, Takeda Y, et al. Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells. Anticancer Res 1993; 13: 1981-8.
23. Lelièvre S, Benchokroun Y, Larsen A. Altered topoisomerase I and II activities in suramin-resistant lung flbrosarcoma cells. Mol Pharmacol 1995; 47: 898-906.
24. Jindal HK, Anderson CW, Davis RG, Vishwanattha JK. Suramin effects DNA synthesis in HeLa cells by inhibition of DNA polymerases. Cancer Res 1990; 50: 7754-7.
25. Fortes PAG, Ellory JC, Lew VL. Suramin: A potent ATPase inhibitor which acts on the inside surface of the sodium pump. Biochem Biophys Acta 1973; 318: 262-72.
26. Jentsch KD, Hunsmann G, Hartmann H, Nickel P. Inhibition of human immunodeficiency virus type I reverse transcriptase by suramin-related compounds. J Gen Virol 1987; 68: 2183-92.
27. Braddock PS, Hu DE, Fan TPD, Stratford IJ, Harris AL, Bicknell R. A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Br J Cancer 1994; 69: 890-8.
28. Gagliardi A, Hadd H, Collins DC. Inhibition of angiogenesis by suramin. Cancer Res 1992; 52: 5073-5.
29. Folkman J. What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 1990; 82: 4-6.
30. Nehls V, Drenckhahn D. A novel microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis. Microv Res 1995; 50: 311-22.
31. Nehls V, Herrman R, Hühnken M. Guided migration as a novel mechanism of capillary network remodeling is regulated by basic fibroblast growth factor. Histochem Cell Biol 1998; 109: 319-29.
32. Nickel P, Haack HJ, Widjaja H, et al. Potentielle filarizide/suraminanloge. Arzneim Forsch 1986; 8: 1153-7.
33. Kassack M, Nickel P. Rapid highly sensitive gradient-narrow bore HPLC determination of suramin and its analogues. J Chromatogr B 1996; 686: 275-84.
34. Carmichael J, De Graff WG, Gadzar AF, Minna JD, Mitchell JB. Evaluation of tetrazolium-based semi-automated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-41.
35. Ciomei M, Pastori W, Mariani M, Sola F, Grandi M, Mongelli N. New sulfonated distamycin A derivatives with bFGF complexing activity. Biochem Pharmacol 1994; 47: 295-302.
36. Wierenga RK, Swinkels B, Michels PAM, et al. Common elements on the surface of glycolytic enzymes from trypanosoma brucei may serve as topogenic signals for import into glycosomes. EMBO J 1987; 6: 215-21.
37. Opperdoes FR, Wierenga RK, Noble MEM et al. Unique properties of glycosomal enzymes. UCLA Symp Mol Cell Biol New Series (Chem Abstr 187648j) 1990; 113: 233-46 ref.
38. Gagliardi ART, Kassack M, Kreimeyer A, Muller G, Nickel P, Collins DC. Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemother Pharmacol 1998, 41: 117-24.
39. Morris AD, Léone S, Guilbaud N, et al. Eriochrome Black T, structurally related to suramin, inhibits angiogenesis and tumor growth in vivo. Anti-Cancer Drugs 1997; 8: 746-55.